I don't know whether a mistake has been made here, but those are interpretations we've had in the submissions we've made. We'll seek clarification on that, because it's a critical component. We wouldn't want to have drugs not identifiable. I think it's an important piece of evidence that needs to be examined here, because there's no intent to try to have less accountability about where these drugs are going.
I would like to turn my attention to the WTO, TRIPS, and Doha.
Mr. Ready, do you believe this CAMR bill goes as far as what was permitted in those organizations in those decisions, or is it less...in what's permitted?